Thrombogenics focuses on nearer-term drug candidates

6 May 2007

Leuven, Belgium-based biotechnology firm ThromboGenics NV has out-licensed the antibodies against platelet glycoprotein Ib (anti-GPIb) and von Willebrand Factor (anti-vWF), which it has been developing as novel anti-thrombotics, so that it can focus resources on its more advanced preclinical programs such as TB-403, an antibody against placental growth factor (P1GF), which is due to enter the clinic later this year.

ThromboGenics also confirmed that its current clinical programs are continuing to progress in line with earlier guidance and noted that its preclinical portfolio currently comprises TB-403 (anti-PlGF, jointly being developed with BioInvent AB, Sweden), PlGF (with Geymonat SpA, Italy), anti-GPIb and anti-VPAC.

Anti-PlGF is a humanized monoclonal antibody that blocks the formation of new blood vessels in solid tumors, reducing the growth and spread of cancer cells. PlGF is a vascular growth factor for the treatment of heart failure, and is moving as planned both in terms of its preclinical evaluation and route of manufacture.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight